At Fosun Pharma USA, we believe science makes the greatest impact when it truly improves patients’ lives.
Our colleagues at Henlius, a subsidiary of Fosun Pharma, recently announced the completion of patient enrollment in the ASTRIDE study evaluating serplulimab* for patients with extensive-stage small cell lung cancer (ES-SCLC).
This milestone represents meaningful progress in research for patients and families affected by small cell lung cancer, reflecting years of collaboration and a shared commitment to making innovative therapies more accessible to those in need.
As we move into the next phase, our U.S. Innovative Medicines team remains focused on evidence generation, medical affairs, and commercial readiness — with patients always at the heart of what we do.
*Serplulimab is not approved for use in the United States (US). Clinical investigation in the US is underway.